Fortress Biotech, Inc. (FBIO) - יחס יתרת חוב לטווח ארוך להון

Current revenue for Fortress Biotech, Inc. (FBIO) is based on licensing fees and the sale of certified drugs. The holding company accumulates stakes in innovative startups, monetizing the scientific achievements of its subsidiaries. An M&A strategy focused on acquiring university assets and partnerships with pharma behemoths accelerate the delivery of medications. An analysis of long-term debt-to-equity visualizes capital density, while 0.30 indicates the current leverage level.

Long-term financing is critical for Fortress Biotech, Inc. (FBIO) when scaling its portfolio of biopharmaceutical subsidiaries. This ratio compares liabilities with a maturity of more than one year to total equity. The trend in the long-term debt-to-equity ratio demonstrates the extent to which asset development depends on borrowed funds. An increase in this metric signals a growing credit burden for the sake of expansion, while a low value confirms the holding company's financial stability.